Asset Details
Do you wish to reserve the book?
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
Do you wish to request the book?
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
2015
Overview
Among patients coinfected with HIV-1 and HCV, a sustained HCV virologic response was reported in 97% of patients treated with 12 weeks of daclatasvir plus sofosbuvir.
Liver disease is a leading cause of death among patients with human immunodeficiency virus type 1 (HIV-1) infection.
1
Coinfection with HIV-1 and hepatitis C virus (HCV) appears to accelerate the course of HCV-associated liver disease
2
–
5
and is widespread, particularly among injection-drug users.
6
The effect of HIV-1 coinfection on the course of HCV disease is reduced but not eliminated by antiretroviral therapy.
7
,
8
Adoption of interferon-based HCV treatments has been low among HIV–HCV coinfected patients
9
,
10
owing to a high adverse-event burden.
11
Furthermore, the rate of sustained virologic response to interferon–ribavirin is lower among patients with HIV–HCV coinfection than among . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Anti-Retroviral Agents - therapeutic use
/ Antiviral Agents - adverse effects
/ Antiviral Agents - therapeutic use
/ Fatigue
/ Female
/ Genotype
/ Headache
/ Hepacivirus - isolation & purification
/ Hepatitis C, Chronic - complications
/ Hepatitis C, Chronic - drug therapy
/ HIV
/ HIV Infections - complications
/ HIV Infections - drug therapy
/ HIV-1
/ Human immunodeficiency virus
/ Humans
/ Imidazoles - adverse effects
/ Imidazoles - therapeutic use
/ Liver
/ Male
/ Nausea
/ Patients
/ Uridine Monophosphate - adverse effects
/ Uridine Monophosphate - analogs & derivatives
